Cargando…

Comparison of the efficacy and safety of pregabalin for postherpetic neuralgia in Chinese and international patients

PURPOSE: Pregabalin is indicated for postherpetic neuralgia (PHN) in multiple countries, including China. This analysis compared pregabalin efficacy and safety in Chinese and international patients with PHN. PATIENTS AND METHODS: Data from Chinese and international randomized, double-blind, placebo-...

Descripción completa

Detalles Bibliográficos
Autores principales: Parsons, Bruce, Pan, Xiaoping, Xie, Li, Chen, YuXuan, Ortiz, Marie, Whalen, Ed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126478/
https://www.ncbi.nlm.nih.gov/pubmed/30214280
http://dx.doi.org/10.2147/JPR.S157856
_version_ 1783353336244731904
author Parsons, Bruce
Pan, Xiaoping
Xie, Li
Chen, YuXuan
Ortiz, Marie
Whalen, Ed
author_facet Parsons, Bruce
Pan, Xiaoping
Xie, Li
Chen, YuXuan
Ortiz, Marie
Whalen, Ed
author_sort Parsons, Bruce
collection PubMed
description PURPOSE: Pregabalin is indicated for postherpetic neuralgia (PHN) in multiple countries, including China. This analysis compared pregabalin efficacy and safety in Chinese and international patients with PHN. PATIENTS AND METHODS: Data from Chinese and international randomized, double-blind, placebo-controlled trials were compared. Pregabalin was administered at fixed (150, 300, or 600 mg/day) or flexible (150–600 mg/day) doses. The main efficacy measure was mean pain score change at endpoint on an 11-point numeric rating scale ranging from 0 = no pain to 10 = worst possible pain. Secondary efficacy measures included proportions of 30% and 50% pain responders, pain-related sleep interference (PRSI) scores, and proportions of Patient Global Impression of Change (PGIC) responders. The incidences of serious adverse events (SAEs) and adverse events (AEs) were used to assess safety. The effect of baseline pain severity on efficacy was tested. The proportions of patients with severe baseline pain who had moderate or mild pain at endpoint were also assessed. RESULTS: A total of 1166 patients were analyzed: 312 Chinese and 854 international. Overall, results were similar between Chinese and international patients. Pregabalin statistically significantly improved mean pain score versus placebo (least squares mean difference [95% CIs]: Chinese, −0.8 [–1.2, −0.5]; international, −1.3 [–1.6, −1.0]; both p<0.001). Pregabalin was statistically significantly better than placebo in Chinese and international patient groups in the proportions of 30% and 50% pain responders, PRSI scores, and proportions of PGIC responders. Baseline pain severity did not affect efficacy, except for some measures in Chinese patients with moderate baseline pain. Similar proportions of pregabalin-treated patients with severe baseline pain had moderate or mild pain at endpoint in both groups. SAE and AE profiles were comparable in Chinese and international patient groups, except incidences were commonly higher in international patients. CONCLUSION: Chinese and international patients with PHN exhibit comparable pregabalin efficacy and safety, highlighting the utility of pregabalin for diverse PHN patient populations.
format Online
Article
Text
id pubmed-6126478
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61264782018-09-13 Comparison of the efficacy and safety of pregabalin for postherpetic neuralgia in Chinese and international patients Parsons, Bruce Pan, Xiaoping Xie, Li Chen, YuXuan Ortiz, Marie Whalen, Ed J Pain Res Original Research PURPOSE: Pregabalin is indicated for postherpetic neuralgia (PHN) in multiple countries, including China. This analysis compared pregabalin efficacy and safety in Chinese and international patients with PHN. PATIENTS AND METHODS: Data from Chinese and international randomized, double-blind, placebo-controlled trials were compared. Pregabalin was administered at fixed (150, 300, or 600 mg/day) or flexible (150–600 mg/day) doses. The main efficacy measure was mean pain score change at endpoint on an 11-point numeric rating scale ranging from 0 = no pain to 10 = worst possible pain. Secondary efficacy measures included proportions of 30% and 50% pain responders, pain-related sleep interference (PRSI) scores, and proportions of Patient Global Impression of Change (PGIC) responders. The incidences of serious adverse events (SAEs) and adverse events (AEs) were used to assess safety. The effect of baseline pain severity on efficacy was tested. The proportions of patients with severe baseline pain who had moderate or mild pain at endpoint were also assessed. RESULTS: A total of 1166 patients were analyzed: 312 Chinese and 854 international. Overall, results were similar between Chinese and international patients. Pregabalin statistically significantly improved mean pain score versus placebo (least squares mean difference [95% CIs]: Chinese, −0.8 [–1.2, −0.5]; international, −1.3 [–1.6, −1.0]; both p<0.001). Pregabalin was statistically significantly better than placebo in Chinese and international patient groups in the proportions of 30% and 50% pain responders, PRSI scores, and proportions of PGIC responders. Baseline pain severity did not affect efficacy, except for some measures in Chinese patients with moderate baseline pain. Similar proportions of pregabalin-treated patients with severe baseline pain had moderate or mild pain at endpoint in both groups. SAE and AE profiles were comparable in Chinese and international patient groups, except incidences were commonly higher in international patients. CONCLUSION: Chinese and international patients with PHN exhibit comparable pregabalin efficacy and safety, highlighting the utility of pregabalin for diverse PHN patient populations. Dove Medical Press 2018-09-03 /pmc/articles/PMC6126478/ /pubmed/30214280 http://dx.doi.org/10.2147/JPR.S157856 Text en © 2018 Parsons et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Parsons, Bruce
Pan, Xiaoping
Xie, Li
Chen, YuXuan
Ortiz, Marie
Whalen, Ed
Comparison of the efficacy and safety of pregabalin for postherpetic neuralgia in Chinese and international patients
title Comparison of the efficacy and safety of pregabalin for postherpetic neuralgia in Chinese and international patients
title_full Comparison of the efficacy and safety of pregabalin for postherpetic neuralgia in Chinese and international patients
title_fullStr Comparison of the efficacy and safety of pregabalin for postherpetic neuralgia in Chinese and international patients
title_full_unstemmed Comparison of the efficacy and safety of pregabalin for postherpetic neuralgia in Chinese and international patients
title_short Comparison of the efficacy and safety of pregabalin for postherpetic neuralgia in Chinese and international patients
title_sort comparison of the efficacy and safety of pregabalin for postherpetic neuralgia in chinese and international patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126478/
https://www.ncbi.nlm.nih.gov/pubmed/30214280
http://dx.doi.org/10.2147/JPR.S157856
work_keys_str_mv AT parsonsbruce comparisonoftheefficacyandsafetyofpregabalinforpostherpeticneuralgiainchineseandinternationalpatients
AT panxiaoping comparisonoftheefficacyandsafetyofpregabalinforpostherpeticneuralgiainchineseandinternationalpatients
AT xieli comparisonoftheefficacyandsafetyofpregabalinforpostherpeticneuralgiainchineseandinternationalpatients
AT chenyuxuan comparisonoftheefficacyandsafetyofpregabalinforpostherpeticneuralgiainchineseandinternationalpatients
AT ortizmarie comparisonoftheefficacyandsafetyofpregabalinforpostherpeticneuralgiainchineseandinternationalpatients
AT whalened comparisonoftheefficacyandsafetyofpregabalinforpostherpeticneuralgiainchineseandinternationalpatients